• Susannah I Thornhill, Axel Schambach, Steven J Howe, Meera Ulaganathan, Elke Grassman, David Williams, Bernhard Schiedlmeier, Neil J Sebire, H Bobby Gaspar, Christine Kinnon, Christopher Baum, and Adrian J Thrasher.
• Centre for Immunodeficiency, Molecular Immunology Unit, Institute of Child Health, University College London, London, UK.
• Mol. Ther. 2008 Mar 1; 16 (3): 590-8.

AbstractGene therapy for X-linked severe combined immunodeficiency (SCID-X1) has proven highly effective for long-term restoration of immunity in human subjects. However, the development of lymphoproliferative complications due to dysregulated proto-oncogene expression has underlined the necessity for developing safer vector systems. To reduce the potential for insertional mutagenesis, we have evaluated the efficacy of self-inactivating (SIN) gammaretroviral vectors in cellular and in vivo models of SCID-X1. Vectors incorporating an internal human elongation factor-1alpha regulatory element were capable of fully restoring the lymphoid differentiation potential of gammac-deficient lineage negative cells. Multilineage lymphoid reconstitution of a murine model was achieved at a similar level to that achieved by a conventional long-terminal repeat (LTR)-regulated vector used in previous clinical trials. Functional proliferative responses to mitogenic stimuli were also restored, and serum immunoglobulin levels were normalized. The reduced mutagenic potential conferred by SIN vector configurations and alternative non-LTR-based regulatory elements, together with proven efficacy in correction of cellular defects provides an important platform for development of the next phase of clinical trials for SCID-X1.

36 keywords...

hide…